An Inflammatory Deal: Bristol Commits Up To $2.3bn To Buy IFM Therapeutics
Most of the deal's value is in milestone fees, but at $300m up front Bristol is giving IFM's Series A investors a 10X return for drug candidates that can inflame non-responsive tumors.
You may also be interested in...
IFM Therapeutics ‘Lather, Rinse, Repeat’ Strategy On Track With $55M Financing
The drug discovery company with a big pharma deal-making track record is launching a new subsidiary, IFM Quattro, and a drug discovery incubator, IFM Discovery. Scrip talked to IFM's new CEO Martin Seidel about what is ahead for the company.
Novartis Dives Into Inflammasome Pool With IFM Tre Purchase
The Swiss major has bought a US biotech that specializes in targeting the NLRP3 pathway in a deal valued at up to $1.58bn.
Fresh Funding Pushes Inflazome Into Clinic With Inflammation Inhibitors
With $46m funding fresh in its pocket, Dublin biotech Inflazome tells Scrip how it will advance its clinical candidates in multiple indications.